Redwood Investments LLC Has $1.86 Million Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Redwood Investments LLC decreased its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 1.3% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 20,790 shares of the medical equipment provider’s stock after selling 283 shares during the period. Redwood Investments LLC’s holdings in Lantheus were worth $1,860,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the business. Assenagon Asset Management S.A. grew its stake in Lantheus by 52.8% in the fourth quarter. Assenagon Asset Management S.A. now owns 25,936 shares of the medical equipment provider’s stock valued at $2,320,000 after purchasing an additional 8,959 shares in the last quarter. Park Avenue Securities LLC grew its stake in shares of Lantheus by 26.4% in the fourth quarter. Park Avenue Securities LLC now owns 2,458 shares of the medical equipment provider’s stock valued at $220,000 after acquiring an additional 513 shares in the last quarter. Empirical Asset Management LLC acquired a new stake in shares of Lantheus in the fourth quarter valued at approximately $323,000. Procyon Advisors LLC raised its holdings in Lantheus by 11.1% in the 4th quarter. Procyon Advisors LLC now owns 3,613 shares of the medical equipment provider’s stock valued at $323,000 after acquiring an additional 361 shares in the last quarter. Finally, Shelton Wealth Management LLC lifted its holdings in shares of Lantheus by 77.8% during the 4th quarter. Shelton Wealth Management LLC now owns 11,969 shares of the medical equipment provider’s stock worth $1,071,000 after acquiring an additional 5,237 shares during the period. 99.06% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on LNTH shares. StockNews.com raised Lantheus from a “hold” rating to a “buy” rating in a research note on Thursday, May 8th. Truist Financial lowered their target price on shares of Lantheus from $127.00 to $117.00 and set a “buy” rating on the stock in a report on Thursday, May 8th. Finally, B. Riley reduced their target price on Lantheus from $127.00 to $122.00 and set a “buy” rating for the company in a report on Friday, March 21st. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Lantheus has an average rating of “Buy” and an average target price of $132.67.

Insider Activity at Lantheus

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of the company’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the transaction, the director now owns 440,399 shares in the company, valued at approximately $41,551,645.65. This represents a 10.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the transaction, the chief financial officer now directly owns 113,860 shares of the company’s stock, valued at $11,445,207.20. The trade was a 8.07% decrease in their position. The disclosure for this sale can be found here. Insiders sold 63,109 shares of company stock worth $6,016,046 in the last 90 days. 1.50% of the stock is owned by corporate insiders.

Lantheus Trading Down 0.2%

NASDAQ LNTH opened at $78.81 on Thursday. The stock has a market cap of $5.40 billion, a P/E ratio of 13.11 and a beta of 0.23. The stock’s fifty day moving average price is $98.18 and its 200-day moving average price is $93.72. Lantheus Holdings, Inc. has a 12 month low of $75.00 and a 12 month high of $126.89.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing analysts’ consensus estimates of $1.64 by ($0.11). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The company had revenue of $372.76 million during the quarter, compared to the consensus estimate of $377.37 million. During the same period in the prior year, the business posted $1.69 earnings per share. Lantheus’s revenue for the quarter was up .8% compared to the same quarter last year. As a group, analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.